Vitrakvi® (larotrectinib) for NTRK Gene Fusion–Positive Tumors

What Vitrakvi® Is and How It Works

Vitrakvi® (larotrectinib) is a targeted cancer medicine. It treats solid tumors that have an NTRK gene fusion. It can be used in adults and children. It is taken by mouth as capsules or oral solution. Typical dosing is twice daily until disease progression or side effects require a change. People often compare vitrackvi cost and vitrackvi price when planning therapy. You can order through YouDrugstore, a licensed Canadian pharmacy in Manitoba that meets Canadian standards. Prescriptions are reviewed by licensed pharmacists before dispensing, and caring chat support is available during posted hours.

Vitrakvi® blocks TRK proteins made by NTRK fusions. These proteins drive tumor growth. By inhibiting TRK signaling, larotrectinib can shrink tumors and keep them controlled. It was granted a tissue‑agnostic approval, so the indication is based on the biomarker, not the tumor site. The vitrackvi fda approval followed strong response rates across many cancers. Health Canada has also authorized this therapy.

We source medicines directly and through licensed, audited international partner pharmacies to provide authentic brands at fair prices and a wide selection. YouDrugstore offers brand and generic medicines at Canadian prices, and also carries OTC items. You can order online or by phone where available.

Dosage and Usage

The prescriber sets the dose. Adults commonly receive 100 mg twice daily. Pediatric dosing is based on body surface area or weight. Treatment continues until disease progression or unacceptable toxicity. Read the vitrackvi label and follow your care team’s plan.

• Take capsules or oral solution at the same times each day.
• Swallow capsules whole. Do not open or crush.
• Measure oral solution with the supplied device. Do not use a kitchen spoon.
• Take with or without food. Avoid grapefruit products.
• If you miss a dose by more than a few hours, follow the plan from your care team. If you vomit after a dose, do not retake; resume the next scheduled dose.

Storage and travel:

• Store capsules and solution at room temperature (20–25°C). Protect from moisture and light.
• Keep the oral solution bottle tightly closed. Do not freeze.
• Ask your pharmacist how long to use the solution after opening.
• When you travel, keep Vitrakvi® in your carry‑on. Use the original labeled container.
• Pack a backup measuring device for the solution.

Benefits and Savings

Larotrectinib offers high response rates in NTRK fusion‑positive tumors across ages and tumor types. Many patients see durable responses. Oral dosing is convenient at home. A pediatric‑friendly liquid is available for children or adults who cannot swallow pills.

Ordering through YouDrugstore can mean meaningful savings. Many customers see 60–80% lower costs compared with typical US prices. You can explore multi‑month supplies when appropriate. Reorder reminders can help you stay on track between scans and clinic visits.

Side Effects and Safety

Most side effects are manageable. Your care team will monitor labs and symptoms. Review the vitrackvi fda information and speak with your oncology team about risks.

• Common: fatigue, dizziness, nausea, vomiting, diarrhea, constipation, cough, headache, abdominal pain, cough, and increased liver enzymes.
• Neurologic effects: confusion, gait disturbance, memory problems, mood changes, or paresthesia can occur.
• Hepatic effects: ALT and AST elevations are reported. Routine liver tests are recommended.
• Other: anemia, decreased appetite, weight gain, and myalgia have been observed.
• Serious: significant liver injury, severe neurotoxicity, hypersensitivity reactions, or fracture risk. Seek urgent care for severe or sudden symptoms.

Drug interactions are important. Strong CYP3A inhibitors can raise larotrectinib levels. Strong CYP3A inducers can lower exposure and reduce benefit. Avoid grapefruit and certain supplements. Tell your team about all medicines and herbs.

Pregnancy and breastfeeding: Vitrakvi® can harm an unborn baby. Effective contraception is needed during treatment and for a period after the last dose as directed by your provider. Do not breastfeed during treatment and for the advised time after the last dose.

Onset Time

Many patients who respond show tumor shrinkage within the first 4–8 weeks. Some responses appear earlier or later. Duration can be long, but it varies by tumor type, prior therapy, and resistance mutations. Imaging schedules follow your oncologist’s plan.

Compare With Alternatives

Rozlytrek® (entrectinib) is another TRK inhibitor with a similar tissue‑agnostic indication. It also targets ROS1 in lung cancer. It has a different side‑effect profile and dosing. Your team may choose between these based on age, tumor location, brain involvement, comorbidities, and prior treatments.

For NTRK‑negative tumors, other targeted or immuno‑oncology options may apply. For example, Zytiga® is used for metastatic prostate cancer and blocks androgen production. Bavencio® is an immunotherapy used in certain urothelial and skin cancers. These are not substitutes for Vitrakvi® but show how precision oncology matches the drug to the tumor’s biology.

Standard chemotherapy, radiation, and surgery can be used alone or with targeted agents. Your oncology team will design a plan based on staging, biomarkers, and goals of care.

Combination Therapy

Vitrakvi® is often used as monotherapy for confirmed NTRK fusion‑positive disease. It can be combined with local treatments such as surgery or radiation when appropriate. Drug‑drug interactions guide systemic combinations. Strong CYP3A inhibitors or inducers can change larotrectinib levels and may require dose changes or avoidance. Always align combination plans with your oncology team’s guidance.

Patient Suitability and Cost-Saving Tips

Patients need documented NTRK gene fusion by a validated test before starting larotrectinib. Comprehensive genomic profiling helps confirm eligibility. The vitrackvi indication covers adults and children with metastatic disease or where surgery would cause severe harm, and who have no satisfactory alternatives or whose tumors progressed after prior therapy. Bayer manufactures Vitrakvi®, and the vitrackvi manufacturer provides supportive materials for clinicians.

Ways to manage costs:

• Ask your prescriber if a multi‑month supply is appropriate to lower per‑month costs.
• Use our reorder reminders so you have medicine on hand before refills are due.
• Compare dosing forms. The oral solution may suit pediatric dosing; capsules may suit adults.
• sale information is posted for current offers and bulk options.

Explore our Cancer category for other oncology therapies. For background reading on targeted therapy and side‑effect care, see Understanding Calquence Medication For Cancer Treatment and Common Darzalex Side Effects And Tips To Manage Them. These articles are educational and not drug‑specific to Vitrakvi®.

The vitrackvi label, vitrackvi fda approval date, and larotrectinib approval history are helpful when discussing timing and monitoring with your team. You can also review vitrackvi uses and the branded dosing tables with your pharmacist. Our pharmacists can address medication questions by phone during office hours.

Authoritative Sources

Bayer Vitrakvi product information

FDA prescribing information for larotrectinib

Health Canada Drug Product Database: Vitrakvi

YouDrugstore is ready to support your oncology care with clear pricing, pharmacist review, and careful packing. Order online with confidence and get prompt, express, cold-chain shipping to your door.

This material is educational and does not replace medical advice. Always follow your oncology team’s instructions and the product monograph for dosing, monitoring, and safety.